FibroGen (FGEN)
1.02
+0.04 (4.08%)
Upcoming Events
Latest Headlines
Form ARS FIBROGEN INC For: Dec 31
April 25, 2024 6:07 AM - SEC Filing
Form DEFA14A FIBROGEN INC
April 24, 2024 5:09 PM - SEC Filing
Form DEF 14A FIBROGEN INC For: Jun 05
April 24, 2024 5:03 PM - SEC Filing
Form 3 FIBROGEN INC For: Apr 22 Filed by: Adib Deyaa
April 24, 2024 4:15 PM - SEC Filing
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Prese
April 24, 2024 4:02 PM - Globe NewsWire
FibroGen (FGEN) Reports Topline Results from Phase 1 Monotherapy Study of FG-3246
April 3, 2024 5:43 AM - StreetInsider
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
April 2, 2024 5:46 PM - Globe NewsWire
Form 4 FIBROGEN INC For: Mar 22 Filed by: Wettig Thane
March 25, 2024 5:59 PM - SEC Filing
Form 4 FIBROGEN INC For: Mar 07 Filed by: Wettig Thane
March 11, 2024 7:07 PM - SEC Filing
FibroGen (FGEN) Appoints Deyaa Adib as Chief Medical Officer
March 11, 2024 7:04 AM - StreetInsider
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
March 11, 2024 7:00 AM - Globe NewsWire
Form 4 FIBROGEN INC For: Mar 06 Filed by: Graham Juan
March 8, 2024 7:20 PM - SEC Filing
Form 4 FIBROGEN INC For: Mar 06 Filed by: Wettig Thane
March 8, 2024 7:18 PM - SEC Filing
Form 4 FIBROGEN INC For: Mar 06 Filed by: Chung Christine
March 8, 2024 7:17 PM - SEC Filing
Form 10-K FIBROGEN INC For: Dec 31
February 26, 2024 4:25 PM - SEC Filing
FibroGen (FGEN) Misses Q4 EPS by 13c
February 26, 2024 4:10 PM - StreetInsider
Form 8-K FIBROGEN INC For: Feb 26
February 26, 2024 4:09 PM - SEC Filing
FibroGen (FGEN) Regains All Rights to Roxadustat from AstraZeneca (AZN)
February 26, 2024 4:07 PM - StreetInsider
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
February 26, 2024 4:06 PM - Globe NewsWire
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea
February 26, 2024 4:05 PM - Globe NewsWire
Form 4 FIBROGEN INC For: Feb 21 Filed by: Wettig Thane
February 23, 2024 8:34 PM - SEC Filing
Form 4 FIBROGEN INC For: Feb 21 Filed by: Chung Christine
February 23, 2024 8:30 PM - SEC Filing
Form 4 FIBROGEN INC For: Feb 21 Filed by: Graham Juan
February 23, 2024 8:29 PM - SEC Filing
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
February 20, 2024 7:00 AM - Globe NewsWire
Form SC 13G FIBROGEN INC Filed by: ARMISTICE CAPITAL, LLC
February 14, 2024 3:38 PM - SEC Filing
Form SC 13G/A FIBROGEN INC Filed by: Point72 Asset Management, L.P.
February 14, 2024 10:08 AM - SEC Filing
Form SC 13G/A FIBROGEN INC Filed by: VANGUARD GROUP INC
February 13, 2024 5:08 PM - SEC Filing
Form SC 13G/A FIBROGEN INC Filed by: PRIMECAP MANAGEMENT CO/CA/
February 12, 2024 4:01 PM - SEC Filing
Form 4 FIBROGEN INC For: Feb 01 Filed by: Wettig Thane
February 5, 2024 8:26 PM - SEC Filing
FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024
February 5, 2024 7:00 AM - Globe NewsWire
Form SC 13G/A FIBROGEN INC Filed by: BlackRock Inc.
January 26, 2024 4:24 PM - SEC Filing
Full Article List
